Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 7/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 7/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23823258 | 0.80 | JAK2 (0.43) | GABBR2GABBR1KDRAURKBPDGFRB | |
| SCHEMBL22860434 | 0.80 | JAK2 (0.43) | GABBR2GABBR1KDRAURKBPDGFRB | |
| SCHEMBL22860432 | 0.79 | GABBR2 (0.42) | GABBR2GABBR1KDRAURKBPDGFRB | |
| SCHEMBL4717413 | 0.79 | GABBR2 (0.42) | GABBR2GABBR1KDRAURKBPDGFRB | |
| SCHEMBL3971399 | 0.79 | GABBR2 (0.40) | GABBR2GABBR1KDRAURKBPDGFRB | |
| SCHEMBL1227148 | 0.77 | MEN1 (0.47) | GABBR2GABBR1CTSKJAK2JAK3 | |
| SCHEMBL1226660 | 0.77 | LRRK2 (0.44) | GABBR2GABBR1CTSKJAK2JAK3 | |
| SCHEMBL1227640 | 0.75 | MERTK (0.49) | JAK2JAK1JAK3KDM4E | |
| SCHEMBL1227632 | 0.75 | MERTK (0.49) | JAK2JAK1JAK3KDM4E | |
| SCHEMBL1227635 | 0.75 | MERTK (0.49) | JAK2JAK1JAK3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | GABBR2 4509/4885GABBR1 4653/4885CTSK 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.